Avient products have not been designed for nor are they promoted or intended for use in: (a) medical devices categorized by either the United States Food and Drug Administration (FDA) or the International Standards Organization (ISO) as an “implant” device; or “Permanent” as defined under US Pharmacopoeia (USP) or ISO standards; or (b) active implantable medical devices as defined in EU Directive 90/385/EEC as amended; or (c) medical devices for “Long Term” use as defined in EU Directive 93/42/EEC as amended. Without limiting the generality of this statement, Avient products shall not be used in any medical device application intended for: (1) exposure to human tissue or body fluids for 30 days or greater; (2) “plastic” (cosmetic or reconstructive) surgery use; (3) reproductive implants or any birth control device; or (4) any critical component in a permanently (greater than 30 days) implanted medical device that supports or sustains human life. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device, including the suitability of all raw materials and components used for its manufacture, and with all applicable laws and regulations. 1.844.4AVIENT www.avient.com

Use of Non GAAP Measures Page 3 -150.00% -100.00% -50.00% 0.00% 50.00% 100.00% 150.00% 200.00% 250.00% 300.00% 350.00% PolyOne S&P 500 Strategy and Execution Drive Results Page 4 • Since 2006, PolyOne stock has expanded approximately 300% vs. a 30% increase in the S&P 500 All time closing high of $26.63 May 28, 2013 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 2013 Portfolio Transformation Highlights • Substantial organic mix improvement drives 29% increase in first quarter EPS – 14th consecutive quarter of double-digit EPS growth • Completed acquisition of Spartech • Announced the creation of a new Specialty segment – Designed Structures and Solutions • Completed the sale of our non-core resin assets • Realigned our Specialty Coatings business into our GCAI segment Page 6 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% PP&S 15% Specialty 60% Distribution 25% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 7 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes resin assets PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items **Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and excludes resin assets 2% 34% 43% 45% 60% 65 – 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2012 2012PF** 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $114M $150M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 8 2007 Q1 2013 2015 Target 1) Operating Income % Specialty: Global Color, Additives & Inks 4.6% 11.7% 12 – 16% Global Specialty Engineered Materials 1.3% 10.1% 12 – 16% Designed Structures & Solutions -- 4.6% 8 – 10% Performance Products & Solutions 6.1% 8.1% 9 – 12% Distribution 3.0% 6.0% 6 – 7.5% 2) Specialty Platform % of Operating Income 20% 60% 65 – 75% 3) ROIC* (after-tax) 7% 9.2% 15% 4) Adjusted EPS Growth N/A 29% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 9 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 50.0% 2006 Q1 2013 $20.3 $41.9 2006 2012 14.3% 27.8% 2006 Q1 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj. EPS: $2.50 Assumptions • Operating margins in mid-range of 2015 targets • No global recession • No investment in incremental PP&S capacity • Completion of 2-3 midsize accretive acquisitions • Housing starts at 85% of 50 year norm by 2015 • Mid single digit revenue CAGR • Remain comfortably below 3X Net Debt / EBITDA Page 11 2012 Rev: $2.9B Adj. EPS: $1.00 First Quarter Financial Highlights • 14th consecutive quarter of double digit adjusted earnings per share growth • 29 percent increase in adjusted EPS  34 percent increase in Specialty operating income  Growth from all regions  Virtually all organic growth • Strengthened our financial position Page 12 • Total Debt at 3/31/13 Less: Cash Net Debt • Available Liquidity Cash ABL Availability Total Liquidity • Net Debt / EBITDA = 2.7x* $169 285 $454 $1,056 169 $887 $50 $360 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2013 ($ millions) Page 13 Coupon Rates: 7.500% 7.375% 5.250% *Pro Forma TTM with no synergies related to Spartech acquisition & excludes resin assets Debt Maturities & Liquidity Summary – 3/31/13 Cash Balance = $169M Net Debt / EBITDA* = 2.7x • Repurchased 840k shares in Q1 2013 • 19.1 million shares are available for repurchase under the current authorization Share Repurchase • Introduced a quarterly dividend in Q1 2011 and increased in Q1 2012 (25%) and Q1 2013 (20%) • Objective of maintaining and growing Dividends • Expanding our sales, marketing, and technical capabilities is top priority • Investing in operational and LSS initiatives (including synergy capture) • CAPEX Organic Growth • Targets that expand our: • Specialty offering • End market presence • Geographic footprint • Synergy opportunities • Adjacent material solutions Acquisitions *TTM with no synergies related to the Spartech acquisition Use of Cash Page 14 Why Invest In PolyOne?

Eliminate complexity of portfolios, go-to-market models and organization 4. to grow double-digits in prioritized businesses through key growth vectors 5. Digital for growth and operational excellence 6. All Rights Reserved 2025 11 Pathway to 20%+ adjusted EBITDA margins 1 Operating leverage • Organic volume growth and SG&A efficiencies from prioritizing resources across the company 2 Mix improvement • Increased sales in higher margin growth platforms 3 Productivity • Manufacturing & sourcing efficiencies • Footprint optimization • Digital technologies Avient margin expansion Schematic illustration only Productivity +400bps margin expansion 20%+ Strategic objective 16.2% 2024 adjusted EBITDA margin +2% +1% Operating leverage +1% Mix improvement Copyright © .

Sanders joined Avient in April 2024 and has responsibility for all legal functions, including contracts and transactions, M&A, compliance, labor relations, digital information, privacy, and intellectual property.

CONSUMER PACKAGED GOODS COMPANY S H A M P O O & C O N D I T I O N E R B O T T L E S A N D C A P S • Achieve a precise color match while ensuring a high amount of post-consumer recycled content (PCR) in the inner layer of the bottle • Reduce development time for quicker approvals and lower costs, and to enable rapid speed to market • Used proprietary Color Prediction Tool to digitally illustrate color possibilities while developing a customized PCR solution • Leveraged Avient’s ColorWorks Design & Technology Center to adjust colors according to the customer’s specifications and accelerate commercialization Smartbatch Combination Colorants & Additives KEY REQUIREMENTS WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION REGULATORY COMPLIANCE LEARN MORE © 2020, All Right Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 https://www.polyone.com/products/thermoplastic-elastomers/versalloy-thermoplastic-elastomers Medical equipment Manufacturer

In the medical industry, plastics are used for a vast array of devices and equipment, including blood and intravenous bags, medical tubing, catheters, lead replacement for radiation shielding, clamps and connectors to bed frames, curtains and sheeting, electronic enclosures and equipment housings. We expect that we will continue to be subject to increasingly stringent environmental, health and safety laws and regulations. Environmental, Health and Safety 4.

In the medical industry, plastics are used for a vast array of devices and equipment, including blood and intravenous bags, medical tubing, catheters, lead replacement for radiation shielding, clamps and connectors to bed frames, curtains and sheeting, electronic enclosures and equipment housings. Safety and Health The top priority at Avient is the safety and health of our associates, and our ultimate goal is to operate injury free. Environmental, Health and Safety 4.

DOCUMENT NUMBER_ SSS-004 CATEGORY DETAIL EC Number 231-545-4 CAS Number 7631-86-9 Chemical Name Silicon Dioxide (SiO2) Structural Formula CHEMICAL IDENTITY Si O O DOCUMENT NUMBER_ SSS-004 HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer No human health hazard has been identified relating to this substance. EFFECT ASSESSMENT RESULT Aquatic Toxicity Not expected to be harmful to aquatic species Daphnia Toxicity Not acutely toxic to daphnia Bacteria Toxicity Not expected to be toxic to bacteria FATE BEHAVIOR Biodegradation Not possible as substance is inorganic Bioaccumulation Potential Low bioaccumulation potential expected PBT/vPvB Conclusion The substance is not a PBT/ vPvB substance EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health No human health hazard was identified.

PHYSICAL/CHEMICAL PROPERTIES DOCUMENT NUMBER_ SSS-002 CATEGORY DETAIL EC Number 236-675-5 CAS Number 13463-67-7 Name Subclass 1 Titanium Dioxide (TiO2) Structural Formula O======Ti====== O PROPERTY DETAIL Physical State Solid Form Crystalline Color White Odor Odorless Melting Point 1560–1843°C Boiling Point 3,000°C Bulk Density 3.9 g/mL at 25°C Water Solubility Immiscible DOCUMENT NUMBER_ SSS-002 HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer Based on available data, TiO2 is not a hazardous substance. Health risks through exposure to TiO2 in its powdered form are presumed to be extremely low since TiO2 is typically fully incorporated into the end product in which it is used. DOCUMENT NUMBER_ SSS-002 EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health The substance is used in industrial settings only.